Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$102.69 USD

102.69
421,572

-0.38 (-0.37%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $102.72 +0.03 (0.03%) 6:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Hold On to Stryker (SYK) Stock Now

by Zacks Equity Research

Challenging global economic conditions and supply-side issues are major deterrents to Stryker's (SYK) top line in the near term. The company's significant exposure to robotics is a positive.

    Zacks Equity Research

    New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales

    by Zacks Equity Research

    Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.

      Zacks Equity Research

      Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y

      by Zacks Equity Research

      Phibro (PAHC) witnesses year-over-year improvement across all segments in Q4.

        Zacks Equity Research

        Wright Medical Buys Cartiva to Boost Lower Extremities Unit

        by Zacks Equity Research

        Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.

          Zacks Equity Research

          Here's Why You Should Hold On to DexCom (DXCM) Stock Now

          by Zacks Equity Research

          DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.

            Zacks Equity Research

            STERIS (STE) Strategic Growth Strong, Competition a Woe

            by Zacks Equity Research

            STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.

              Zacks Equity Research

              Bruker to Expand Molecular Diagnostics Arm With Hain Buyout

              by Zacks Equity Research

              Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.

                Zacks Equity Research

                Omnicell Patient Engagement Unit to Aid Medication Adherence

                by Zacks Equity Research

                Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.

                  Zacks Equity Research

                  Here's Why You Should Invest in Integer (ITGR) Stock Now

                  by Zacks Equity Research

                  Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.

                    Zacks Equity Research

                    Cerner, Duke Clinical Research Launch Risk Calculator App

                    by Zacks Equity Research

                    Cerner (CERN) launches new Risk Calculator app that will check cardiac risk. The company's relentless efforts to digitize its EHR systems is commendable.

                      Zacks Equity Research

                      Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails

                      by Zacks Equity Research

                      Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.

                        Zacks Equity Research

                        Hill-Rom (HRC) Touches 52-Week High: What's Driving It?

                        by Zacks Equity Research

                        Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.

                          Zacks Equity Research

                          Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates

                          by Zacks Equity Research

                          Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.

                            Zacks Equity Research

                            Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now (Revised)

                            by Zacks Equity Research

                            Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.

                              Zacks Equity Research

                              Align Technology International Growth Solid, Rivalry Rife

                              by Zacks Equity Research

                              Align Technology's (ALGN) Invisalign Technology prospects and growth in North America and outside hold great potential for the stock, particularly in the Asia-Pacific and EMEA regions.

                                Zacks Equity Research

                                Why You Should Add Chemed (CHE) Stock to Your Portfolio Now

                                by Zacks Equity Research

                                Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.

                                  Zacks Equity Research

                                  Here's Why You Should Invest in Illumina (ILMN) Stock Now

                                  by Zacks Equity Research

                                  Illumina (ILMN) gains on strategic partnerships and international prospects.

                                    Zacks Equity Research

                                    Ecolab's New Aquanomic Enhances Laundry Operations at Hotels

                                    by Zacks Equity Research

                                    Ecolab's (ECL) new Aquanomic 2.0 Low-Temp Solid Laundry Program likely to boost Global Institutional segment.

                                      Zacks Equity Research

                                      Cerner (CERN) Strong on EHR Prospects, Competition Intense

                                      by Zacks Equity Research

                                      Cerner's (CERN) strong EHR prospects and global outlook aid the company; margins continue to decline.

                                        Zacks Equity Research

                                        Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC

                                        by Zacks Equity Research

                                        Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.

                                          Zacks Equity Research

                                          DaVita Healthcare Partners' New Facility Now in Los Angeles

                                          by Zacks Equity Research

                                          DaVita's (DVA) incessant efforts to upgrade services, global expansion initiatives and active acquisitions are impressive.

                                            Zacks Equity Research

                                            Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now

                                            by Zacks Equity Research

                                            Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.

                                              Zacks Equity Research

                                              Masimo (MASI) Scales a 52-Week High: What's Driving It?

                                              by Zacks Equity Research

                                              Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.

                                                Zacks Equity Research

                                                Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4

                                                by Zacks Equity Research

                                                Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.

                                                  Zacks Equity Research

                                                  Avanos Medical (AVNS) Jumps: Stock Rises 5.5%

                                                  by Zacks Equity Research

                                                  Avanos Medical (AVNS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.